Skip to main content
. Author manuscript; available in PMC: 2020 Apr 27.
Published in final edited form as: J Alzheimers Dis. 2020;74(4):1085–1095. doi: 10.3233/JAD-191039

Table 1.

Demographics of cognitively normal participants at baseline (n=335) who either remained cognitively normal and who had no biomarker evidence of amyloid (non-converter) throughout or individuals who became cognitively impaired (converter).

Non-Converter Converter P
N 290 45
Age (years) (mean (SD)) 67.3 (9.1) 77.6 (6.8) <0.001
Education (years) (mean (SD)) 16.1 (2.5) 15.9 (3.3) 0.622
Gender (% female) 183 (63.1) 25 (55.6) 0.420
APOE ε4+ (%) 79 (29.2) 15 (33.3) 0.504
Race (%) 0.854
Asian 2 (0.7) 0 (0.0)
African-American 26 (9.0) 4 (8.9)
Non-Hispanic White 260 (90.3) 41 (91.1)

APOE= Apolipoprotein E SD= standard deviation